Document Classification

Section Type: METHODS

Text: Two hundred twenty-three patients were randomized to receive either six courses of a multiple-drug combination (MDC) regimen (Adriamycin [ADR ; doxorubicin ; Farmitalia Carlo Erba, Milan, Italy] 25 mg/m2 intravenously [i. v.] on day 1 ; etoposide [VP16] 120 mg/m2 i. v. on day 1 ; cyclophosphamide [CPA] 500 mg/m2 i. v. on day 1 ; cisplatin 60 mg/m2 i. v. on day 8 ; vindesine [VDS] 3 mg/m2 i. v. on day 8 ; vincristine [VCR] 2 mg i. v. on day 15 ; methotrexate [MTX] 100 mg/m2 i. v. on day 15), or a standard chemotherapy (SC) regimen (ADR 50 mg/m2 i. v. on day 1 ; CPA 1 g/m2 i. v. on day 1 ; VP16 80 mg/m2 i. v. on days 1 to 3).